PharmaCyte Biotech Inc Market Cap ($3.65 Million)
Market Cap & Net Worth: PharmaCyte Biotech Inc (PMCB)
PharmaCyte Biotech Inc market cap. PharmaCyte Biotech Inc (NASDAQ:PMCB) has a market capitalization of $3.65 Million ($3.65 Million) as of November 5, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #29125 globally and #5968 in its home market, demonstrating a -2.86% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying PharmaCyte Biotech Inc's stock price $0.34 by its total outstanding shares 10735649 (10.74 Million). Also see PMCB cash flow metrics for how efficiently the company converts equity into cash flow.
PharmaCyte Biotech Inc Market Cap History (2015–2026)
PharmaCyte Biotech Inc market cap history from 2015 to 2026. Data shows change from $740.48 Million to $3.65 Million (-43.10% CAGR). Check PMCB stock price for real-time trading data and today's change.
Index Memberships
PharmaCyte Biotech Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.61 Trillion | 0.00% | #839 of 976 |
|
NASDAQ Composite
IXIC
|
$40.20 Trillion | 0.00% | #2685 of 3165 |
Weight: PharmaCyte Biotech Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
PharmaCyte Biotech Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how PharmaCyte Biotech Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore PharmaCyte Biotech Inc (PMCB) net asset momentum to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of PMCB by Market Capitalization
Companies near PharmaCyte Biotech Inc in the global market cap rankings as of November 5, 2026. Also see PharmaCyte Biotech Inc (PMCB) total assets for a full breakdown of the balance sheet.
Key companies related to PharmaCyte Biotech Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #180 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #368 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #414 globally with a market cap of $68.22 Billion USD ( AU$96.41 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #494 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #180 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $530.76 |
| #368 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $973.36 |
| #414 | CSL Ltd | AU:CSL | $68.22 Billion | AU$198.72 |
| #494 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $228.44 |
Market Capitalization of PharmaCyte Biotech Inc (2015–2026)
Market capitalization of PharmaCyte Biotech Inc from 2015 to today. Between 2015 and today, PharmaCyte Biotech Inc's market cap moved from $740.48 Million to $ 3.65 Million, with a yearly change of -43.10%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $3.65 Million | -53.02% |
| 2025 | $7.77 Million | -53.89% |
| 2024 | $16.85 Million | -27.31% |
| 2023 | $23.19 Million | -26.28% |
| 2022 | $31.46 Million | +17.20% |
| 2021 | $26.84 Million | -75.13% |
| 2020 | $107.90 Million | -83.46% |
| 2019 | $652.22 Million | +9.46% |
| 2018 | $595.86 Million | -33.69% |
| 2017 | $898.62 Million | -62.53% |
| 2016 | $2.40 Billion | +223.84% |
| 2015 | $740.48 Million | -- |
End of Day Market Cap According to Different Sources
On Nov 4th, 2026 the market cap of PharmaCyte Biotech Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $3.65 Million USD |
| MoneyControl | $3.65 Million USD |
| MarketWatch | $3.65 Million USD |
| marketcap.company | $3.65 Million USD |
| Reuters | $3.65 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About PharmaCyte Biotech Inc
PharmaCyte Biotech, Inc., a biotechnology company, focused on developing and preparing to commercialize cellular therapies for cancer using live cell encapsulation technology in the United States. The company's cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer. It also devel… Read more